| Document |
Document Title |
|
WO/2022/116981A1 |
An application of a polyanionic cellobioside compound, particularly, an application of a compound as represented by formula II in preparation of a medication for treatment of a related disease or disorder caused by 2019-nCoV infection. T...
|
|
WO/2022/119950A1 |
A chewable composition comprising an active pharmaceutical ingredient (API) composition, a surfactant composition, a binding composition, and a gelling composition in a sufficient amount to provide a cohesive gelled product. The API comp...
|
|
WO/2022/114810A1 |
The present invention relates to a pharmaceutical composition and the like, for preventing or treating pulmonary or airway fibrosis, comprising a progranulin (PGRN) protein or active fragments thereof as an active ingredient. The present...
|
|
WO/2022/114091A1 |
The present invention relates to a method for predicting the prognosis of patients with lung adenocarcinoma. The present invention relates to a method for predicting the prognosis after cancer removal of patients with lung adenocarcinoma...
|
|
WO/2022/113887A1 |
A purpose of the present invention is to provide a novel assessment method that enables early detection, assessment of severity, and assessment of therapeutic effect, etc., of chronic inflammatory retinal diseases including age-related m...
|
|
WO/2022/114077A1 |
The present disclosure addresses the problem of providing at least a technology for skin improvement. Said problem is solved by a skin improving composition containing lactobionic acid and an aglycone of an isoflavone and/or a glycoside ...
|
|
WO/2022/114216A1 |
The present invention addresses the problem of providing a therapeutic agent that is more efficacious for treating nerve disorders, said therapeutic agent comprising a culture supernatant of mesenchymal stem cells. The present inventio...
|
|
WO/2022/114881A1 |
The present invention provides a pharmaceutical composition for preventing or treating a wound or scar, comprising benzbromarone as an active ingredient. The present invention has confirmed that benzbromarone inhibits the function of hea...
|
|
WO/2022/114058A1 |
The present invention addresses the problem of providing a therapeutic agent for pulmonary fibrosis that has high therapeutic effect. The present invention provides a therapeutic agent for pulmonary fibrosis that comprises a compound rep...
|
|
WO/2022/113799A1 |
This antisense nucleic acid is for a target sequence at positions 96-330 or positions 400-530 in the base sequence represented by SEQ ID NO: 1, has a base sequence complementary to a sequence formed of 10 or more bases appearing consecut...
|
|
WO/2022/114111A1 |
[Problem] To provide a composition that can mature or stabilize blood vessels. [Solution] This composition contains pentosan polysulfate and/or a salt thereof as an active ingredient, and is useful for treating and/or preventing diseases...
|
|
WO/2022/114187A1 |
The present invention provides a compound for treating or preventing diseases caused by excessive mitochondrial divisions. The present invention relates to a compound represented by formula (1) (in the formula: R1 and R1' are each inde...
|
|
WO/2022/114189A1 |
Provided is a compound that exerts an anticancer effect based on the inhibition of CHK1. The present disclosure has been completed based on the finding that a compound represented by formula (1) or a pharmaceutically acceptable salt ther...
|
|
WO/2022/113693A1 |
A therapeutic agent for muscular dystrophy that includes a medium-chain triglyceride as an active ingredient.
|
|
WO/2022/113987A1 |
Provided are: a novel compound represented by formula (1); and an antiviral agent against positive-strand RNA viruses and an inhibitor of lipid droplet formation, which contain said compound as an active ingredient. In formula (1), R rep...
|
|
WO/2022/114878A1 |
The present invention enables quick and accurate diagnosis or prediction of fibrosis as well as effective prevention, relief or treatment of fibrosis.
|
|
WO/2022/114105A1 |
The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity β-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass% or higher and in...
|
|
WO/2022/114138A1 |
Provided is a novel method for producing a (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-[(4-fluorophenyl)methoxy
]bicycle[3.1.0]hexane-2,6-dicarboxylic acid. This production method is characterized by relying on the conversion from a compound rep...
|
|
WO/2022/113991A1 |
A type III collagen production promoter that comprises a composition containing isostearyl ascorbyl phosphate or a metal salt thereof represented by the chemical formula and a hydrolyzed eggshell membrane component as water-soluble compo...
|
|
WO/2022/114152A1 |
The purpose of the present invention is to provide a novel agent capable of activating sirtuin 6 (SIRT 6). A SIRT 6 activator comprising urolithin as an active ingredient.
|
|
WO/2022/115609A1 |
Disclosed herein are compositions comprising adipogenic cells that are useful for the treatment, prevention, or amelioration of diseases or disorders.
|
|
WO/2022/114459A1 |
The present invention relates to a pharmaceutical composition for preventing or treating organ fibrosis comprising monomethyl fumarate as an active ingredient, the pharmaceutical composition comprising monomethyl fumarate as an active in...
|
|
WO/2022/107745A1 |
[Problem] To develop a novel therapeutic agent for viral diseases such as corona virus infection. [Solution] A therapeutic agent or prophylactic agent for viral diseases that comprises a compound having an activity of inhibiting the func...
|
|
WO/2022/107853A1 |
The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent i...
|
|
WO/2022/106615A1 |
The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-
2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase a...
|
|
WO/2022/106425A1 |
The invention relates to the treatment or prevention of liver failure.
|
|
WO/2022/109573A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...
|
|
WO/2022/106919A1 |
The invention relates to an active substance composition from vitamins, amino acids and electrolytes for treating stress-related symptoms and symptoms caused by excess physical strain.
|
|
WO/2022/105877A1 |
Disclosed are a pharmaceutical composition comprising a bilobalide component and a pharmaceutically acceptable carrier or excipient, and a pharmaceutical preparation of a bilobalide component comprising a bilobalide component, a pharmace...
|
|
WO/2022/109043A1 |
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose...
|
|
WO/2022/107755A1 |
The present invention provides: a novel acridinium salt expressed by formula (I); and a method for producing this novel acridinium salt. (In the formula, R1 represents a C1-C6 alkyl group or a C1-C6 alkyloxy group; R2 represents a hydrog...
|
|
WO/2022/109595A1 |
The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-
2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase a...
|
|
WO/2022/109602A1 |
The present disclosure provides a method for preventing and/or treating fatigue and/or depression in a subject in need of such prevention and/or treatment, comprising administering to said subject an effective amount of Crassocephalum ra...
|
|
WO/2022/102557A1 |
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...
|
|
WO/2022/102713A1 |
This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-
1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 re...
|
|
WO/2022/102715A1 |
Provided is a novel cancer treatment means in which a reversible BTK inhibitor and an immunity checkpoint inhibitor are combined. For example, provided is a pharmaceutical composition for treating cancer wherein BTK inhibitor (I-A) and a...
|
|
WO/2022/099431A1 |
Provided are the crystalline solid meglumine salts of (R)-5-(4-chlorophenyl)-1-isopropyl-2-methyl-4-(3-(4-(4-((4-(
(1-(phenylthio)-4-(4- ((phosphonooxy)methyl)piperidin-1-yl)butan-2-yl)amino)-3-((t
rifluoromethyl)sulfonyl)phenyl)sulfonam...
|
|
WO/2022/102788A1 |
The present invention provides a composition that has an effect of enhancing the gene expression of adrenomedullin. One or more embodiments of the present invention pertain to a composition for enhancing adrenomedullin gene expression,...
|
|
WO/2022/102731A1 |
The present invention addresses the problem of providing an effective cancer treatment method. The present invention provides a cancer treatment method that combines a standard treatment with an EP4 antagonist and an immune checkpoint in...
|
|
WO/2022/102687A1 |
This therapeutic agent for cancer is for use in treating a cancer in a subject, contains an L-type amino acid transporter 1 (LAT1) inhibitor, and is characterized by suppressing the proliferation or metastasis of cancer cells by inhibiti...
|
|
WO/2022/103352A1 |
The invention in particular relates to the use of intravenous immunoglobulin in the preparation of a drug for the treatment of Cutis Verticis Gyrata disease.
|
|
WO/2022/103833A1 |
Articles and methods related to the administration of biomolecules to subjects using metal-organic frameworks are generally described. In some embodiments, an article is described, the article comprising a substrate comprising an adhesiv...
|
|
WO/2022/101492A1 |
The present invention relates to a nucleic acid molecule encoding a fusion protein comprising (i) a secretory signal peptide; (ii) a lipocalin-derived binding protein specifically binding to an exogenous ligand; and (iii) a glycosylphosp...
|
|
WO/2022/102634A1 |
Provided are a pharmaceutical composition and a treatment method that are excellent in terms of antitumor effect and safety. A pharmaceutical composition and a treatment method characterized in that an antibody-drug conjugate, in which a...
|
|
WO/2022/098192A1 |
The present invention relates to a composition for preventing, ameliorating or treating cachexia, comprising a complex extract of Cyperi rhizoma and Zanthoxyli pericarpium. The complex extract of the present invention exhibits the effect...
|
|
WO/2022/097727A1 |
The present invention provides a single-stranded antisense oligonucleotide or a pharmaceutically acceptable salt thereof for regulating the expression and/or function of the RPS25 gene. In the single-stranded antisense oligonucleotide, e...
|
|
WO/2022/097731A1 |
The objective of the present invention is to reduce the cellular cytotoxicity of an algefacient and/or strengthen the cooling sensation of the algefacient. It was discovered that the cellular toxicity of menthol, which is the algefacient...
|
|
WO/2022/097837A1 |
The present invention relates to a composition for suppressing side effects of amlodipine, the composition being capable of maximizing the effects of hypertension treatment by effectively reducing side effects caused by a toxic dose and ...
|
|
WO/2022/098153A1 |
The present invention relates to: a pharmaceutical composition for preventing or treating cachexia, containing Bojungikgitang, an extract thereof or a fraction thereof; a method for preventing or treating cachexia, comprising a step of a...
|
|
WO/2022/096637A1 |
The present invention relates to a Lactate/Ketone body ester for preservation of vital organ function and combat inflammation and cancer growth. In particular, the present invention relates to a Lactate/Ketone body ester with the benefic...
|
